ArticlePloS one2026
Dengue severity and profiles of complement activation and immune mediators: A multicenter cohort study in Indonesia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue virus (DENV) infection can manifest as dengue fever (DF) or dengue hemorrhagic fever (DHF), although DHF often becomes clinically apparent around defervescence. How complement components and other immune responses evolve over the course of illness from the febrile to recovery phase remains incompletely defined. This study characterized circulating complement activation and immune mediators in DF and DHF using paired febrile and early-recovery samples.
methodsWe conducted a multicenter prospective cohort study at five hospitals in Indonesia between November 2024 and October 2025. Patients with laboratory-confirmed dengue were classified as DF or DHF. Plasma concentrations of PTX3, C5a, IL-6, IL-10, IL-8, and CXCL10 were quantified in paired febrile and early recovery phase samples. Between-group differences, within-patient changes between the two time points, and correlations among immune mediators were assessed using appropriate statistical methods.
resultsWe included 110 confirmed dengue cases in the analysis. PTX3 and IL-10 levels were significantly higher in DHF than in DF during early recovery, whereas no mediator differed significantly between severity groups during the febrile phase. Across phases, C5a increased significantly from febrile to early recovery in DHF but not in DF, whereas PTX3 decreased significantly in DF but not in DHF. Correlations among mediators were generally weak to moderate, with a reproducible PTX3-IL-10-CXCL10 module observed across both phases.
conclusionThe measured mediators did not distinguish DF from DHF during the febrile phase, but differences emerged in early recovery, with higher PTX3 and IL-10 in DHF. Across phases, C5a increased significantly from febrile to early recovery in DHF, whereas PTX3 decreased significantly only in DF. A PTX3-IL-10-CXCL10 module was observed at both time points. Together, these patterns suggest that within-patient changes around defervescence or in the early recovery may be informative and warrant evaluation in larger, prospectively timed cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.